Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical Health Equity

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Podcast

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

“I believe in the concept of a universal cancer vaccine,” said Elias Sayour, a pediatric oncologist at the University of Florida. “I think if this fails in a prospective phase III trial, I still believe we can engineer a vaccine that works prospectively.”

January 14, 2026

Vol.52 No.1

Clinical

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.

January 09, 2026

Vol.52 No.1

By Sara Willa Ernst and Jacquelyn Cobb

Clinical Roundup

Fred Hutch researchers launch free online tool to assess CRC risk

Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.

January 09, 2026

Vol.52 No.1

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

YOU MAY BE INTERESTED IN

With five-year cancer survival at an all-time high, does this mean people are living longer?

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

Fred Hutch researchers launch free online tool to assess CRC risk

Renew today!

Subscriber content

Never miss an issue!

Login